Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC-Reference-Cited by-同舟云学术

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC

Published:2018-09-18 Issue:24 Volume:24 Page:6195-6203
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Le Xiuning,Puri Sonam,Negrao Marcelo V.,Nilsson Monique B.,Robichaux Jacqulyne,Boyle Theresa,Hicks J. Kevin^ORCID,Lovinger Katherine L.,Roarty Emily,Rinsurongkawong Waree,Tang Ming,Sun Huiying,Elamin Yasir,Lacerda Lara C.,Lewis Jeff,Roth Jack A.,Swisher Stephen G.^ORCID,Lee J. Jack,William William N.,Glisson Bonnie S.,Zhang Jianjun,Papadimitrakopoulou Vassiliki A.,Gray Jhanelle E.,Heymach John V.^ORCID

Funder

MD Anderson Cancer Center

NIH

UT Lung SPORE

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 302 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer;Lung Cancer;2024-09

2. PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC;Clinical Cancer Research;2024-07-17

3. EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis;Journal of Personalized Medicine;2024-07-15

4. The efficacy of almonertinib and anlotinib combination therapy for advanced non‐small‐cell lung cancer patients who continued to experience cancer progression during third‐generation EGFR‐TKI treatment: a retrospective study;Thoracic Cancer;2024-07-10

5. EGFR V834L and L858R Comutation Is Associated With Response to Osimertinib in Non–Small-Cell Lung Cancer;JCO Precision Oncology;2024-07